-
A Review of Utility Data Used in Health Technology Assessments From the Perspective of a Health Technology Assessment Body
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of a Digital Health Intervention for Screening and Managing Hypertension at Primary Care Level in Kenya: A Microsimulation Model
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Pembrolizumab in Combination With Enfortumab Vendotin for First-Line Treatment of Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Sep 9, 2025, 16:22 PM -
Systematic Literature Review (SLR) of First-Line (1L) Treatments of Patients With Advanced or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma (GEA)
Sep 9, 2025, 16:22 PM -
Bridging the Survival Extrapolation Gap in Health Economic Models: A Case Study on Spline-Based Survival Analysis Using ML-NMR to Address Complex Hazard Function
Sep 9, 2025, 16:22 PM -
Surrogate Outcome Validation Within the New EU HTA Guidance Framework: Practical Considerations From an Industry Perspective Based on Experience From HTA Germany
Sep 9, 2025, 16:22 PM -
Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility Data
Sep 9, 2025, 16:22 PM -
The Growing Role of Real-World Evidence (RWE) to Support Efficacy in EMA Oncology Approvals: Light at the End of the Tunnel
Sep 9, 2025, 16:22 PM -
Real-World Uptake of SGLT2i Usage in Patients With Chronic Kidney Disease or Heart Failure: A German Claims Data Analysis
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Adult Vaccination Programs and HTA of Vaccines Approaches in the US, UK, and France: Lessons for Poland
Sep 9, 2025, 16:22 PM -
Trends in Receipt of Preventive Healthcare Services from 2020-2024: US Electronic Health Records (EHR) Database Analysis of 118 Million Patients
Sep 9, 2025, 16:22 PM -
Structured Expert Elicitation for Survival Outcomes: Insights From NICE Technical Support Document 26
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Safety of Targeted NSCLC Therapies Using the FDA Adverse Event Reporting System (FAERS) Differing Experience of Healthcare Providers (HCP) From EU vs. US
Sep 9, 2025, 16:22 PM -
Do We Need to Measure Social Impact of Innovative Drugs?
Sep 9, 2025, 16:22 PM -
Comparative Analysis of Reimbursement Decisions for Advanced Oncology Combination Therapies in England and Japan
Sep 9, 2025, 16:22 PM -
Trends and Disparities in Prostate Cancer Incidence Prevalence and Survival: A SEER Analysis 2000-2022
Sep 9, 2025, 16:22 PM -
Systematic Review of Real-World Data on the Effectiveness and Safety Profiles of First-Line Therapies in Chronic Lymphocytic Leukemia
Sep 9, 2025, 16:22 PM -
Pragmatic Advice to Improve Assessment Schedule of Preference-Based Measures of Health to Estimate Utilities in Clinical Trials
Sep 9, 2025, 16:22 PM -
A New Approach for Modeling the Complexity of the Impact of Caring Using the Family and Caregiving Effects
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of STRIDE (Tremelimumab + Durvalumab) vs. Atezolizumab + Bevacizumab for Unresectable Hepatocellular Carcinoma: Qatari Payer and Societal Perspectives
Sep 9, 2025, 16:22 PM
